Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suvorexant on Sympathetic Neural Activity in Chronic Insomnia
NCT03768713Phase 4Unknown
- Sponsor
- Montana State University
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Insomnia comparing Suvorexant with Placebo (2 arms). Primary endpoints: Sympathetic nerve activity at 8 weeks and Baroreflex sensitivity at 8 weeks. Status: unknown.
02
Drugs
suvorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03768713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768713.